Type 2 diabetes market to increase to $47 billion in 2023
As physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs, new research suggests.
According to the latest report from Decision Resources Group, as the robust type 2 diabetes pipeline increases the range of therapeutic options available to physicians, the overall type 2 diabetes market within the G7 (USA, France, Germany, Italy, Spain, UK and Japan) is set for rapid expansion, with growth from sales of over $26 billion in 2013 to $47 billion in 2023.
Other key findings from the Pharmacor advisory service, titled Type 2 Diabetes, include:
- SGLT-2 inhibitors: The recently launched SGLT-2 inhibitors are experiencing rapid uptake in the major markets, despite known associations with genital mycotic and urinary tract infections; the first-to-market entrants canagliflozin (Johnson & Johnson’s Invokana) and dapagliflozin (AstraZeneca’s Farxiga/Forxiga) are set to garner significant sales.
- GLP-1 receptor agonists: The GLP-1 receptor agonist class is also set for significant growth during the forecast period, with the emergence of a number of once-weekly agents set for considerable uptake. As the only once-weekly agent to thus far demonstrate non-inferiority to the market-leading liraglutide (Novo Nordisk’s Victoza), dulaglutide (Eli Lilly’s Trulicity, which was just approved in the USA on September 19) is set to garner significant uptake.
- Increasingly stringent reimbursement: In response to the increasing cost burden of type 2 diabetes, payer and reimbursement agencies are becoming increasingly stringent with regard to reimbursable therapies. Payers are increasingly restricting the number of options available to physicians, particularly for drug classes with multiple therapy options, such as the DPP-IV inhibitors.
- Biosimilar insulins: The emergence of biosimilar insulins during the forecast period, in particular Eli Lilly/Boehringer Ingelheim’s biosimilar insulin glargine (Basaglar/Abasria), are set to enjoy considerable uptake in response to payer concerns over the escalating costs of existing insulin formulations. However, the cost-savings associated with biosimilars are less than those associated with generic small molecules.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze